감염병 빅데이터 거래소

상세정보
샘플정보
연락처 및 데이터 관리
제약 및 취소환불 규정
상품 Q&A

상세정보

데이터등록일	데이터 수정일	데이터 이용기한	판매제공처
2022-12-07	2023-07-25	무기한	BLT
데이터 제공포맷	데이터 제공방식	데이터 파일용량	데이터 상품구분
csv/zip	다운로드	162.81 MB	dataset

■ 데이터상품설명 ICD 질병분류코드에 정의된 감염질환을 기준으로 질병별로 정리된 특허데이터를 가공해 제공합니다. 본 데이터 상품은 원문에 가까운 데이터의 제공이 목적이며, 질병/특허번호/날짜/권리자/명칭/초록 등의 정보가 수록되어있습니다. ■ 간략 통계 수록 감염병: 약 600종 (정의된 감염질환 1200여개에 대해 모두 스크리닝) 수록 특허수: 약 4만건 (2023년 02월 현재기준) 질병당 특허수 :평균 222건 (최소1 최대 6977건) ■ 데이터 내용설명 아래와 같은 데이터를 포함하고 있습니다 1) 질병정보 (질병ID/질병코드/질병명) 2) 특허번호정보 (특허ID/출원번호/등록번호) 3) 특허날짜정보 (출원일자/등록일자) 4) 특허권리자 5) 특허원문 (발명의명칭/초록) ■ 참고: ICD10 질병분류코드 코로나바이러스감염증-19 [U07.1] 콜레라 [A00] 결핵 [A15-A19] 디프테리아 [A36] 패혈증 [A40-41] 크로이츠펠트-야콥병 [A81.0] 바이러스수막염 [A87] 지카 바이러스 질환 [A92.5] 황열 [A95] 뎅기 [A97] 에볼라바이러스병 [A98.4] 헤르페스바이러스[단순헤르페스] 감염 [B00] 대상포진 [B02] 바이러스간염 [B15-B19] 인체면역결핍바이러스병 [B20-B24] 감염성 단핵구증 [B27] 백선증 [B35] 칸디다증 [B37] 샤가스병 [B57] 연충증 [B65-B83] 메티실린 내성 황색포도상구균 [U82.1]

샘플정보

컨텐츠ID	컨텐츠영어명	컨텐츠한국어명	컨텐츠대분류명	질병분류코드	국가코드	특허ID	특허출원번호	특허공개번호	특허등록번호	특허출원일자	특허출원공개일자	특허등록일자	특허최초공보발행일자	현재특허권리자그룹	특허발명의명칭제목	특허초록	메인CPC특허분류코드	전체CPC특허분류코드목록	CPC특허분류코드개수	메인IPC특허분류코드	전체IPC특허분류코드목록	IPC특허분류코드개수
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US00010160778B2	15/522692	20170334937	10160778	20151027	20171123	20181225	20171123	Concert Pharmaceuticals	Pyrimidine phosphonic acid esters	This invention relates to compounds of Formula (I):	C07F9/6512	C07F9/6512\|A61K31/675\|A61P31/20	3	C07F9/6512	C07F9/6512\|A61K31/675	2
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US20060239970A1	10/543216	20060239970		20040123	20061026		20061026	University of Rochester	Herpesvirus amplicon particles	The invention includes methods for delivering therapeutic agents to a patient through administration of herpesvirus amplicon particles generated by a cell that stably express herpes simplex virus (HSV) immediate early 3 (IE3) gene.	C12N15/86	C12N15/86\|A61K48/0091\|C12N2710/16643\|A61K48/00	4	A61K48/00	A61K48/00\|C12N15/86	2
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US20080241127A1	11/955595	20080241127		20071213	20081002		20081002	Dyax	Methods of Making Passive Immunotherapies	Methods for isolating antibodies useful as passive immunotherapies are described.	G01N33/6854	G01N33/6854\|Y02A50/30\|C07K16/08	3	A61K39/395	A61K39/395\|C40B30/04	2
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US20090004744A1	12/113169	20090004744		20080430	20090101		20090101	Vaxiion Therapeutics	MINICELLS AS VACCINES	The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.	C12N15/74	C12N15/74\|Y02A50/30\|A61K2039/522\|A61K39/02	4	C12N15/75	C12N15/75\|C12N15/74	2
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US20110065753A1	12/873705	20110065753		20100901	20110317		20110317	Unither Virology	METHODS OF TREATING POXVIRAL INFECTIONS	Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Poxyiridae family using iminosugars, such as DNJ derivatives.	A61K31/445	A61K31/445\|A61P31/20\|A61P31/12\|A61K31/452\|C07D211/46	5	A61K31/445	A61K31/445\|C12N5/02\|A61P31/20	3
941042	Rubella with other complications	기타 합병증을 동반한 풍진	피부 및 점막병변이 특징인 바이러스감염	B06.8	US	US00006369068B1	09/319859		6369068	19990611		20020409	20020409	GlaxoSmithKline (GSK)	Amino substituted pyrimidine containing compounds	<p>Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.</p>	C07D401/14	C07D401/14\|C07D405/14\|C07D403/04\|C07D405/12\|C07D409/14\|C07D401/12	6	A61K31/506	A61K31/506\|C07D401/14\|C07D403/04\|C07D401/12\|C07D405/14\|C07D405/12\|C07D409/14	7
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US20140363523A1	14/372650	20140363523		20130117	20141211		20141211	Concert Pharmaceuticals	DEUTERATED ALPHA-LIPOIC ACID	The present invention provides a compound of Formula (I), wherein: each X is independently hydrogen or deuterium; and at least one X is deuterium.	C07D339/04	C07D339/04\|A61P3/04\|A61P3/00\|A61K45/06\|A61K31/385	5	C07D339/04	C07D339/04\|A61K45/06\|A61K31/385	3
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US20150111899A1	14/580335	20150111899		20141223	20150423		20150423	InterMune	PIRFENIDONE THERAPY AND INDUCERS OF CYTOCHROME P450	The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.	A61K31/4418	A61K31/4418\|Y02A50/30\|A61K31/496\|A61K31/4412	4	A61K31/4412	A61K31/4412\|A61K31/496	2
211710	Viral infections characterized by skin and mucous membrane lesions	피부 및 점막병변이 특징인 바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B00-B09	US	US20170071991A1	15/310556	20170071991		20150507	20170316		20170316	Virttu Biologics	Oncolytic Virus and Aurora Kinase Inhibitor for the Treatment of Cancer	The use of an oncolytic virus and an aurora kinase inhibitor in the treatment of cancer is disclosed.	A61K35/763	A61K35/763\|A61P35/00\|A61K45/06\|C12N2710/16632\|A61K31/55\|C12N7/00\|A61P43/00	7	A61K31/55	A61K31/55\|C12N7/00	2
211712	Varicella [chickenpox]	수두	피부 및 점막병변이 특징인 바이러스감염	B01	US	US20140094383A1	14/044631	20140094383		20131002	20140403		20140403	The Ohio State University	Tethered Lipoplex nanoparticle Biochips And Methods Of Use	Disclosed are compositions and methods for the use of lipoplex nanoparticle chips and arrays in the detection of/diagnosis of a disease or condition.	G01N33/56983	G01N33/56983\|Y02A50/30\|G01N33/5432	3	G01N33/569	G01N33/569	1
211713	Zoster [herpes zoster]	대상포진	피부 및 점막병변이 특징인 바이러스감염	B02	US	US20090270427A1	12/433388	20090270427		20090430	20091029		20091029	Cancer Research Technology	PURINE DERIVATIVES	The present invention relates to compounds of formula 1	C07D473/16	C07D473/16\|A61P31/20\|A61P25/28\|A61P43/00\|A61P11/00\|A61P31/18\|A61P25/00\|A61P35/02\|A61P9/00\|A61P31/14\|A61P17/14\|A61P35/00\|A61P3/10\|A61P31/12\|A61P17/06\|A61P31/22\|A61P29/00\|A61P13/12	18	A61K31/52	A61K31/52\|C07D473/16\|C12N9/99\|A61P35/00	4
211713	Zoster [herpes zoster]	대상포진	피부 및 점막병변이 특징인 바이러스감염	B02	US	US20190256899A1	16/134497	20190256899		20180918	20190822		20190822	Accugenomics	NUCLEIC ACID AMPLIFICATION AND USE THEREOF	The invention features compositions and methods that are useful for the measurement of the quantity of a nucleic acid target in a sample.	C12Q1/6832	C12Q1/6832\|C12Q2600/158\|C12Q1/686\|C12Q2600/156\|C12Q1/701\|C12Q1/689\|C12Q1/6886	7	C12Q1/6832	C12Q1/6832\|C12Q1/689\|C12Q1/6886\|C12Q1/70\|C12Q1/686	5
211716	Measles	홍역	피부 및 점막병변이 특징인 바이러스감염	B05	US	US20120029015A1	13/258654	20120029015		20100323	20120202		20120202	Marciniak Andrzej\|Turski Waldemar	Novel medical use of kynurenic acid, its precursors and derivatives	The invention relates to the use of kynurenic acid derivatives of general formula (I),	A61K31/47	A61K31/47\|Y02A50/30\|A61P5/48\|A61P1/18	4	A61K31/47	A61K31/47\|A61P1/18\|C07D215/48	3
211717	Rubella [German measles]	풍진	피부 및 점막병변이 특징인 바이러스감염	B06	US	US00006562832B1	09/446036		6562832	19991215		20030513	20030513	GlaxoSmithKline (GSK)	Substituted imidazole compounds	<p>Novel 1,4,5-subsituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.</p>	C07D403/04	C07D403/04\|C12Q1/6827	2	C07D233/54	C07D233/54\|C07D403/04\|C12Q1/68	3
211717	Rubella [German measles]	풍진	피부 및 점막병변이 특징인 바이러스감염	B06	US	US20050075352A1	10/884788	20050075352		20040702	20050407		20050407	GlaxoSmithKline (GSK)	3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors	Novel substituted quinazoline compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.	C07D401/06	C07D401/06\|C07D239/80	2	A61K31/517	A61K31/517	1
941043	Rubella arthritis	풍진 관절염	피부 및 점막병변이 특징인 바이러스감염	B06.8.0	US	US00005929076B	09/101525		5929076	19981029		19990727	19990727	GlaxoSmithKline (GSK)	Cycloalkyl substituted imidazoles	<p>Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy.</p>	C07D403/04	C07D403/04	1	A61K31/505	A61K31/505\|C07D403/04	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008637663B2	12/441812	20100022578	8637663	20071116	20100128	20140128	20100128	Janssen Sciences Ireland UC	Macrocyclic inhibitors of hepatitis C virus	Inhibitors of HCV replication of formula (I)	C07D491/056	C07D491/056\|C07D401/12\|A61P31/14\|A61P1/16\|A61K31/427\|Y02A50/30\|C07D491/04\|A61P43/00\|A61P31/12\|A61K31/4741\|C07D491/048	11	C07D225/04	C07D225/04\|A61K31/4709\|A61P31/12\|A61K31/4741\|C07D245/04	5
941051	Vaccinia	우두	피부 및 점막병변이 특징인 바이러스감염	B08.0.3	US	US00006177076B1	09/206425		6177076	19981207		20010123	20010123	Thomas Jefferson University	Method of treating bladder cancer with wild type vaccinia virus	<p>Methods of treating bladder cancer in a patient by administration of wildtype vaccinia virus are provided.</p>	A61K9/0034	A61K9/0034\|A61K39/285\|A61K39/12\|C12N2710/24132\|A61P35/00	5	A61P35/00	A61P35/00\|A61K39/285\|A61K9/00\|A61K35/76	4
941047	Other orthopoxvirus infections	기타 오르토폭스바이러스감염	피부 및 점막병변이 특징인 바이러스감염	B08.0	US	US20130302367A1	13/880814	20130302367		20111021	20131114		20131114	Hokkaido University	VIRUS VECTOR FOR PRIME/BOOST VACCINES, WHICH COMPRISES VACCINIA VIRUS VECTOR AND SENDAI VIRUS VECTOR	[Problem]	A61K39/39	A61K39/39\|C12N2740/16134\|C12N15/86\|C12N2740/16034\|A61K39/21\|C12N2710/24143\|A61K39/12\|Y02A50/30\|A61K2039/545\|C12N2760/18843\|A61K2039/53	11	A61K39/39	A61K39/39	1
941053	Exanthema subitum [sixth disease]	돌발발진[제6병]	피부 및 점막병변이 특징인 바이러스감염	B08.2	US	US20090227637A1	12/097350	20090227637		20061206	20090910		20090910	Bayer Healthcare	DIARYL UREAS FOR TREATING VIRUS INFECTIONS	The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.	A61K31/44	A61K31/44\|A61P31/12	2	A61K31/44	A61K31/44\|A61P31/12	2
941061	Foot-and-mouth disease	족구병	피부 및 점막병변이 특징인 바이러스감염	B08.8.1	US	US20060222662A1	10/546031	20060222662		20040217	20061005		20061005	responsif	Composition to be administered to a living being and method for marking agents	The invention relates to compositions to be administered to a living being, a method for marking agents that are administered to living beings, the use thereof, and an accelerated test.	C07K14/005	C07K14/005\|A61K47/6901\|A61K47/646\|C12N2770/22022\|A61K2039/5258\|A61K39/00	6	A61K39/12	A61K39/12\|A61K38/10\|A61K38/08	3
941061	Foot-and-mouth disease	족구병	피부 및 점막병변이 특징인 바이러스감염	B08.8.1	US	US20080194504A1	10/588414	20080194504		20050204	20080814		20080814	Advanced Bionutrition	Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals	The invention is directed to compositions (e.g., feeds, feed supplements, and therapeutic products) and methods for inhibiting an animal pathogen using RNA-interference technology.	C12N15/111	C12N15/111\|C12N2310/53\|A61P31/10\|C12N2310/14\|A61P31/04\|C12N2310/111\|C12N15/1131\|C12N2320/32\|A61P31/12	9	A61K31/7105	A61K31/7105\|A61P31/04\|A61P31/10\|A61P31/12	4
941061	Foot-and-mouth disease	족구병	피부 및 점막병변이 특징인 바이러스감염	B08.8.1	US	US20160130565A1	14/935061	20160130565		20151106	20160512		20160512	Princeton University	Method to Produce Virus in Cultured Cells	A method for improving virus production in a host cell infected with the virus is provided.	C12N7/00	C12N7/00\|C12N2710/16751\|C12N2710/16151	3	C12N7/00	C12N7/00	1
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00005427909B	07/940242		5427909	19920908		19950627	19950627	Immuno	Oligonucleotides and determination system of HCV genotypes	<p>Hepatitis C virus oligonucleotides and a system to determine hepatitis C virus genotypes with polymerase chain reaction utilizing those oligonucleotides as primers.</p>	C12Q1/707	C12Q1/707	1	C12P19/34	C12P19/34\|C12Q1/70\|C12Q1/68\|C07H21/04	4
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00005633388B	08/625717		5633388	19960329		19970527	19970527	Wyeth	Compounds, compositions and methods for treatment of hepatitis C	<p>Heterocyclic substituted carboxamides are useful in prophylaxis and treatment of hepatitis C virus infections.</p>	C07D235/20	C07D235/20\|C07D235/18	2	C07D403/12	C07D403/12\|A61K31/415\|C07D235/18\|C07D235/20	4
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00005759795B	08/612987		5759795	19960308		19980602	19980602	MSD (Merck & Company)	Assay for determining inhibitors of ATPase	<p>This invention provides materials and methods for identifying inhibitors of a Hepatitis C Virus NS3 protein ATPase. Methods for making and purifying such an ATPase are also provided by this invention.</p>	C12Q1/66	C12Q1/66\|C12Q1/42	2	C12Q1/42	C12Q1/42\|C12Q1/66	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00005780219B	08/371583		5780219	19950112		19980714	19980714	Biolucent\|Cytyc\|Cytyc Surgical Products\|Direct Radiography\|Gen-Probe\|Gen-Probe Prodesse\|Hologic\|Suros Surgical Systems\|Third Wave Technologies	Nucleic acid amplification oligonucleotides and probes to human hepatitis B virus	<p>Amplification oligonucleotides and hybridization assay probes specific for Human Hepatitis B Virus.</p>	C12Q1/706	C12Q1/706	1	C07H21/04	C07H21/04\|C12Q1/68\|C12Q1/70	3
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00005830905B	08/625718		5830905	19960329		19981103	19981103	Wyeth	Compounds, compositions and methods for treatment of hepatitis C	<p>Derivatives of piperidine are useful in prophylaxis and treatment of hepatitis C virus infections.</p>	C07D401/14	C07D401/14\|C07D211/62\|C07D211/58	3	C07D401/06	C07D401/06\|A61K31/445\|C07D401/14\|C07D211/62\|C07D211/58	5
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00005939423B	08/834378		5939423	19970416		19990817	19990817	Sciclone Pharmaceuticals	Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir	<p>Treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral- effective amount of thymosin alpha 1 (T&agr;1) and an antiviral- effective amount of famciclovir.</p>	A61K31/52	A61K31/52\|A61K38/2292	2	A61K31/52	A61K31/52\|A61K38/22	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00006017756B	08/193627		6017756	19940207		20000125	20000125	Wilderness Place Holdings	Method and reagent for inhibiting hepatitis B virus replication	<p>An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis B virus.</p>	C12N15/1131	C12N15/1131\|A61P31/14\|C12N2310/121\|A61K38/00\|C12Q1/6876	5	A61P31/14	A61P31/14\|C12Q1/68\|C12N15/113\|A61K38/00	4
968871	hepatitis C	C형간염	바이러스간염	B17.1\|B18.2	US	US20050152875A1	11/046296	20050152875		20050128	20050714		20050714	Toray Industries	Preventives for reinfection after liver transplantation	Reinfection with the hepatitis C virus after liver transplantation is protected by administering IFN-β before liver transplantation, and thus IFN-β is useful as a reinfection protecting agent.	A61K38/215	A61K38/215\|A61P31/14\|A61P31/00\|A61P1/16\|A61P1/00	5	A61K38/21	A61K38/21	1
968871	hepatitis C	C형간염	바이러스간염	B17.1\|B18.2	US	US20140206017A1	14/122984	20140206017		20120601	20140724		20140724	Gilead Sciences	LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF	The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) poly-peptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided.	G01N33/573	G01N33/573\|A61K2039/505\|C07K16/40	3	G01N33/573	G01N33/573	1
211726	Human immunodeficiency virus [HIV] disease	인체면역결핍바이러스병	인체면역결핍바이러스병	B20-B24	US	US00007569723B2	12/014185	20080114068	7569723	20080115	20080515	20090804	20080515	Boehringer Ingelheim International	Benzoic acid derivatives as non nucleoside reverse-transcriptase inhibitors	Compounds of formula (I):	C07C235/68	C07C235/68\|A61P31/18\|C07C255/56\|C07C235/24	4	C07C229/08	C07C229/08\|A61K31/195\|A61P31/18\|C07C229/02	4
968871	hepatitis C	C형간염	바이러스간염	B17.1\|B18.2	US	US20160031927A1	14/772818	20160031927		20140219	20160204		20160204	Alexandre Vasilievich Ivachtchenko\|Asavi	Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof	Compounds of the general formula 1, stereoisomers, pharmaceutically acceptable salts, and/or hydrates, solvates or crystalline forms thereof	C07H19/10	C07H19/10\|A61P31/12\|C07F9/65586\|A61P43/00\|A61P31/16\|A61P31/14	6	C07H19/10	C07H19/10	1
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00006964771B1	08/923783		6964771	19970904		20051115	20051115	Quadrant Drug Delivery	Method for stably incorporating substances within dry, foamed glass matrices	The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical.	C12N1/04	C12N1/04\|A61K9/2095\|A61K9/2018\|Y02A50/30	4	A61K9/14	A61K9/14\|A61K9/20\|A61K9/00\|A61K47/00\|C12N1/04	5
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00007022688B1	08/985667		7022688	19971205		20060404	20060404	Wyeth	Use of 17β-dihydroequilenin as an antioxidant	This invention provides a method of using 17β-dihydroequilenin or a pharmaceutically acceptable salt of 17β-dihydroequilenin-3-sulfate ester as an antioxidant.	A61K31/56	A61K31/56	1	A61K31/56	A61K31/56	1
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00007473688B2	11/516435	20070078122	7473688	20060906	20070405	20090106	20070405	Bristol-Myers Squibb	Indolobenzazepine HCV NS5B inhibitors	The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.	C07D491/14	C07D491/14\|A61P31/14\|A61P31/00\|C07D487/04	4	A61K31/55	A61K31/55\|A61P31/00\|C07D487/04\|C07D223/14	4
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00007135462B2	10/992548	20050267040	7135462	20041118	20051201	20061114	20051201	Bristol-Myers Squibb	Hepatitis C virus inhibitors	Hepatitis C virus inhibitors are disclosed having the general formula:	A61K31/40	A61K31/40\|A61P43/00\|A61P31/12\|C07K5/0827\|A61K38/00\|C07K5/0808\|A61P1/16\|A61K31/4709\|A61P31/14	9	A61K38/00	A61K38/00\|A61K38/05\|C07K5/083\|C07K5/08\|A61K31/695\|A61K38/06\|A61K31/4709\|A61K38/21\|A61K31/40\|C07K5/06	10
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00007173004B2	10/825693	20050090432	7173004	20040416	20050428	20070206	20050428	Bristol-Myers Squibb	Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus	A compound of formula I:	C07K5/0804	C07K5/0804\|C12P41/005\|A61K38/00\|C12P13/04\|A61P1/16\|A61P31/14\|A61P43/00\|C12P7/62\|A61P31/22	9	A61K38/00	A61K38/00\|C07K5/12\|C12P41/00\|C07K5/083\|C07K7/00\|C12P13/04\|A61K38/12\|C07K\|C12P7/62	9
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00009624183B2	14/798879	20150315165	9624183	20150714	20151105	20170418	20151105	Gilead Sciences	Process for the preparation of a fluorolacton derivative	A novel process for the preparation of a fluorolactone derivative of the formula	C07D263/26	C07D263/26\|A61P31/14\|Y02P20/55\|C07D413/06\|C07D307/33	5	C07D307/33	C07D307/33\|C07D263/26\|C07D413/06	3
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008193346B2	12/328380	20090156800	8193346	20081204	20090618	20120605	20090618	Enanta Pharmaceuticals	Process for making macrocyclic oximyl hepatitis C protease inhibitors	The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds.	C07D487/04	C07D487/04\|C07D519/00\|C07K5/081\|C07K5/0804\|C07K5/0802	5	C07D245/02	C07D245/02\|C07K5/12\|C07K5/08	3
211731	Mumps	볼거리	기타 바이러스질환	B26	US	US20190218524A1	16/366278	20190218524		20190327	20190718		20190718	Princeton University	Method to Produce Virus in Cultured Cells Supplemented With Alpha-Ketoglutarate	A method is provided to improve virus production is an infected host cell by culturing the infected cell in an effective amount of alpha-ketoglutarate.	C12N7/00	C12N7/00\|C12N2710/16151\|C12N2501/999\|C12N2500/36\|C12N5/0018\|C12N2710/16751	6	C12N7/00	C12N7/00\|C12N5/00	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00007425552B2	11/304902	20060189602	7425552	20051216	20060824	20080916	20060824	Anadys Pharmaceuticals	Pyridazinone compounds	The invention is directed to pyridazinone compounds of Formula I and pharmaceutical compositions containing compounds of Formula I	C07D417/04	C07D417/04\|C07D513/04\|C07D417/14\|A61P31/14\|A61P31/12	5	C07D513/04	C07D513/04\|A61K31/549\|C07D417/04\|C07D498/02	4
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00007476499B2	11/762607	20080090225	7476499	20070613	20080417	20090113	20080417	The Leland Stanford Junior University	Methods of identifying anti-viral agents	The present invention provides methods of identifying candidate anti-viral agents.	C12Q1/18	C12Q1/18	1	C12Q1/70	C12Q1/70\|C12Q1/18	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00007501433B2	11/104281	20050261329	7501433	20050412	20051124	20090310	20051124	Taiwanj Pharmaceuticals	Opioid and opioid-like compounds and uses thereof	The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.	C07D221/28	C07D221/28\|C07D489/08\|C07D489/02\|C07D489/00\|A61K31/485	5	A61K31/485	A61K31/485\|C07D489/00\|C07D489/08\|C07D221/28\|C07D519/00\|C07D489/02	6
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US20030009775A1	10/157099	20030009775		20020528	20030109		20030109	The Leland Stanford Junior University	Mouse model for hepatitis C	<p>A rodent model for HCV infection is obtained by introducing into rodents which harbor a liver-specific defect an expression system which comprises an HCV replicon or a reverse transcript thereof and at least a nucleotide sequence encoding a rescue protein which remedies the defect. </p>	A01K67/027	A01K67/027	1	A01K67/027	A01K67/027	1
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008183277B2	11/995560	20080262058	8183277	20060728	20081023	20120522	20081023	Janssen Sciences Ireland UC	Macrocylic inhibitors of hepatitis C virus	Inhibitors of HCV replication of formula (I)	C07D487/04	C07D487/04\|A61P31/14\|A61P31/00\|C07D403/04\|A61P43/00\|A61P31/12	6	A61K31/407	A61K31/407\|C07D487/04\|A61P31/12\|A61K31/41	4
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00010603299B2	16/502150	20190380995	10603299	20190703	20191219	20200331	20191219	Steven Baranowitz	Prevention and treatment of viral infections	The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.	A61K31/343	A61K31/343\|Y02A50/30\|A61P31/14	3	A61K31/24	A61K31/24\|A61K31/343\|A61P31/14\|A61K31/34\|A61K31/65	5
968871	hepatitis C	C형간염	바이러스간염	B17.1\|B18.2	US	US20120142605A1	13/319004	20120142605		20100505	20120607		20120607	Amgen	METHODS OF TREATING PSORIASIS	The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid.	A61K31/57	A61K31/57\|A61P17/06\|A61K38/191	3	A61K38/16	A61K38/16\|A61P17/06	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008198045B2	12/297488	20090311744	8198045	20070419	20091217	20120612	20091217	Ratiopharm	Expression of O-glycosylated therapeutic proteins in prokaryotic microorganisms	The invention relates to methods of producing an O-glycosylated soluble therapeutic protein in a prokaryotic microorganism by co-expressing the therapeutic protein and a heterologous glycosyltransferase that transfers a sugar moiety to an amino acid acceptor on the therapeutic protein.	C12P21/005	C12P21/005\|A61P43/00	2	C12P21/06	C12P21/06\|C07H21/04\|C12N1/20\|C12N1/21\|C12N15/00\|C12N9/10\|C12P19/04	7
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008377994B2	12/299997	20090306224	8377994	20060510	20091210	20130219	20091210	Evonik Degussa	Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions	The use of Sch?lpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described.	A61K9/1611	A61K9/1611\|A61K9/1694	2	A61K47/00	A61K47/00\|A61K31/19\|A61K47/02\|A61K9/20	4
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008426360B2	12/269941	20090149491	8426360	20081113	20090611	20130423	20090611	Enanta Pharmaceuticals	Carbocyclic oxime hepatitis C virus serine protease inhibitors	The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:	C07D471/04	C07D471/04\|C07D225/04\|C07D409/12\|C07D405/12\|C07D245/04\|C07D401/12	6	A61K31/4709	A61K31/4709\|A61K31/4375\|A61K38/00\|C07D215/00\|C07D245/02\|C07D471/12	6
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00009134228B2	14/402849	20150129766	9134228	20130521	20150514	20150915	20150514	GSK (GLaxoSmithKline) Biologicals	Method for determining a concentration of a polysorbate species in a mixture	The present invention relates to a method of measuring polysorbates, such as polysorbate 80, using Attenuated Total Reflectance-Fourier Transform Infrared spectroscopy (ATR-FTIR).	G01N21/3577	G01N21/3577\|G01N2021/3595\|G01J3/28\|G01N21/552\|G01N21/55	5	G01J5/02	G01J5/02\|G01N21/35\|G01N21/55\|G01J3/28	4
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008486384B2	12/446487	20100303761	8486384	20071029	20101202	20130716	20101202	LIVACTUS	Lipidized interferon and methods of treating viral hepatitis	The present invention is directed to methods and compositions useful in increasing in mammals the absorption and retention of polypeptides. The invention provides lipid-conjugated interferon having increased liver uptake and increased plasma half-life.	A61K38/21	A61K38/21\|A61P1/16\|A61K47/543\|A61P31/14\|A61P31/12	5	A61K38/21	A61K38/21\|A61P1/16\|A61P31/14\|C07K14/56\|A61K38/00	5
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008530182B2	12/746649	20110201039	8530182	20081205	20110818	20130910	20110818	Centers for Disease Control and Prevention	Viral protein quantification process and vaccine quality control therewith	A process of quantifying proteins in a complex mixture is provided. The invention has utility in quantifying proteins in a complex preparation of uni- or multivalent commercial or research vaccine preparations.	G01N30/7233	G01N30/7233\|G01N2030/045\|G01N2030/8831\|G01N2030/8868	4	C12Q1/37	C12Q1/37	1
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008709999B2	13/260334	20120028978	8709999	20100326	20120202	20140429	20120202	Presidio Pharmaceuticals	Substituted bicyclic HCV inhibitors	Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.	C07D403/14	C07D403/14\|C07D409/14\|C07D417/14\|A61P31/14\|C07D413/14\|C07D405/14	6	A61K38/00	A61K38/00\|A01N37/18\|C07D405/14\|A61K31/4164\|A61P31/14\|A61K31/427\|C07D401/14\|C07D403/14\|A61K31/454\|C07D417/14\|A61K31/5377\|C07D413/14	12
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008754105B2	13/109395	20110237621	8754105	20110517	20110929	20140617	20110929	Janssen Sciences Ireland UC	Macrocyclic inhibitors of hepatitis C virus	Inhibitors of HCV replication of formula (I)	C07D487/04	C07D487/04\|A61P31/14\|A61P31/12\|C07D413/12\|A61P43/00	5	A01N43/42	A01N43/42\|A61K31/47\|A61K31/4725\|C07D498/04\|A61K31/4709\|A61P31/14\|C07D401/12	7
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00008911934B2	12/739648	20100311038	8911934	20081031	20101209	20141216	20101209	Debiopharm\|Katholieke Universiteit Leuven (Ku Leuven)	Near full-genome assay of HCV drug resistance	The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.	C12Q1/707	C12Q1/707	1	C12Q1/70	C12Q1/70\|C07H21/00	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00009212168B2	13/667197	20130115194	9212168	20121102	20130509	20151215	20130509	Theravance Biopharma	Hepatitis C virus inhibitors	The invention provides compounds of formula (I):	A61K31/496	A61K31/496\|A61P31/14\|A61P43/00\|A61P31/12\|C07D413/14\|C07D491/113\|C07D405/14\|C07D409/14\|C07D401/14\|A61K45/06\|A61P1/16\|A61K31/5377\|A61K31/541	13	C07D401/14	C07D401/14\|C07D405/14\|C07D409/14\|C07D413/14\|C07D491/113\|A61P31/14\|A61K31/541\|A61K31/5377\|C07F5/02\|A61K31/7052\|C07D417/14\|A61K31/496\|A61K31/7056\|A61K38/21	14
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00009242983B2	14/247609	20140221382	9242983	20140408	20140807	20160126	20140807	Gerhard Puerstinger\|Katholieke Universiteit Leuven (Ku Leuven)	Viral inhibitors	Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A),	C07D471/04	C07D471/04\|A61P31/12\|A61P31/00\|A61P31/14	4	A61K31/4353	A61K31/4353\|A61K31/437\|C07D471/04	3
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00009527904B2	14/484842	20150010578	9527904	20140912	20150108	20161227	20150108	California Institute of Technology (CALTECH)	Delivery of proteins using adeno-associated virus (AAV) vectors	Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors.	C07K16/109	C07K16/109\|C12N7/00\|C12N2750/14141\|A61P31/12\|A61P31/14\|C07K16/1045\|A61P31/18\|A61P31/20\|C12N2750/14143	9	A61K48/00	A61K48/00\|A01K67/00\|C12N7/00\|C07K16/10\|C07H21/04	5
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00009637485B2	14/926393	20160122344	9637485	20151029	20160505	20170502	20160505	F. Hoffmann-La Roche	6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection	The invention provides novel compounds having the general formula:	C07D471/04	C07D471/04\|A61P1/16\|A61P31/20	3	A61K31/4985	A61K31/4985\|C07D471/04	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00010034893B2	14/169387	20140219958	10034893	20140131	20140807	20180731	20140807	Enanta Pharmaceuticals	5, 6-D2 uridine nucleoside/tide derivatives	In one aspect, the invention provides compounds represented by Formula I,	A61K31/7072	A61K31/7072\|C07H19/10\|C07H19/11\|A61K31/13\|A61K31/7056\|A61K38/21\|A61K45/06\|C07H19/06	8	C07H19/06	C07H19/06\|C07H19/10\|C07H19/11\|A61K31/7072\|A61K45/06\|A61K31/13\|A61K31/7056\|A61K38/21	8
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00010160743B2	14/891895	20160115149	10160743	20140516	20160428	20181225	20160428	Janssen Sciences Ireland UC	Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B	Inhibitors of HBV replication of formula (I)	C07D333/38	C07D333/38\|A61P31/22\|A61P31/12\|C07D409/12\|A61P43/00	5	C07D333/38	C07D333/38\|C07D409/12	2
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US00010301268B2	15/263033	20170066724	10301268	20160912	20170309	20190528	20170309	The Salk Institute for Biological Studies	Analogs of fexaramine and methods of making and using	Novel compounds having a formula	C07D231/56	C07D231/56\|C07C2602/42\|C07B59/002\|C07B59/001\|C07C2601/14\|C07C233/63\|C07B2200/05	7	C07D231/56	C07D231/56\|C07C233/63\|C07B59/00	3
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US20020037868A1	09/880945	20020037868		20010615	20020328		20020328	Institut Pasteur	Method for detecting hepatitis C	<p>The present invention provides methods of detecting hepatitis C virus. </p>	G01N33/5767	G01N33/5767\|C12N5/163\|C07K16/109\|G01N2333/186\|C12Q1/707\|C12Q1/686	6	C12Q1/70	C12Q1/70\|G01N33/543\|G01N33/53\|G01N33/537\|A61K31/70\|C12P19/34\|A01N43/04	7
968872	hepatitis D	D형간염	바이러스간염	B16.0-1\|B18.0	US	US20090156473A1	12/325598	20090156473		20081201	20090618		20090618	Virologik	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL INFECTIONS AND/OR TUMOR DISEASES BY INHIBITING PROTEIN FOLDING AND PROTEIN BREAKDOWN	The invention relates to the treatment of viral diseases with at least one proteasome inhibitor and one inhibitor of protein-folding enzymes.	A61K31/00	A61K31/00\|A61K31/325\|Y02A50/30\|A61P35/00\|A61P31/12\|A61K31/4965	6	A61K38/13	A61K38/13\|A61K31/436\|A61K38/00	3
211719	Viral hepatitis	바이러스간염	바이러스간염	B15-B19	US	US20050208653A1	11/125577	20050208653		20050510	20050922		20050922	ES Cell International	Method of isolating bile duct progenitor cells	The present invention relates to a substantially pure population of viable bile duct progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny.	A61K35/39	A61K35/39\|C12N5/0678\|A61K35/413\|C12N2501/148\|C12N5/0672\|A61K35/407\|C12N2501/115\|A61P31/20\|C12N2501/113\|A61P31/04\|C12N2501/11\|A61P1/16	12	C12N5/08	C12N5/08\|C12N5/06	2
211720	Acute hepatitis A	급성 A형간염	바이러스간염	B15	US	US00008716262B2	12/645765	20110015146	8716262	20091223	20110120	20140506	20110120	Gilead Sciences	Nucleoside phosphoramidates	A nucleoside compound having activity against hepatitis C virus is disclosed.	C07H19/20	C07H19/20\|A61P31/12\|A61P31/14\|A61P31/16\|A61P31/18\|A61P31/20\|A61P43/00\|Y02A50/30	8	A01N43/04	A01N43/04\|A61K31/70\|C07H19/04\|A61K31/7076\|A61P31/16\|A61P31/14\|A61P31/20\|C07H19/20	8
941087	HIV disease resulting in encephalopathy	뇌병증을 유발한 인체면역결핍바이러스병	인체면역결핍바이러스병	B22.0	US	US20080188510A1	11/419816	20080188510		20060523	20080807		20080807	EISAI R&D Management	NOVEL METHODS USING ZONISAMIDE	The present invention relates to usefulness of zonisamide as a pharmaceutical composition for treating dementia or cognitive impairment.	A61K31/423	A61K31/423\|A61P25/00\|A61K31/445\|A61K31/4355	4	A61K31/423	A61K31/423\|A61K31/4355\|A61K31/445\|A61P25/00	4
968871	hepatitis C	C형간염	바이러스간염	B17.1\|B18.2	US	US20110112100A1	12/868342	20110112100		20100825	20110512		20110512	Pfizer	Hepatitis C Virus Inhibitors	The present invention relates to compounds of the formula (I)	C07D403/14	C07D403/14\|C07D403/04\|C07D401/14\|A61P31/14\|C07F7/0812\|C07F5/025	6	A61K31/498	A61K31/498\|C07D241/36\|A61P31/14	3
211720	Acute hepatitis A	급성 A형간염	바이러스간염	B15	US	US20120202794A1	13/353538	20120202794		20120119	20120809		20120809	Gilead Pharmasset	COMPOUNDS	Disclosed herein are compounds useful for treating a viral infection, such as HCV.	C07D241/08	C07D241/08\|C07D261/12\|C07D413/04\|A61P31/12\|C07D497/04\|C07D409/04\|C07D417/06\|C07D405/06\|C07D413/14\|C07D403/06\|C07D413/06	11	A61K31/551	A61K31/551\|C07D417/06\|A61K31/496\|C07D241/04\|A61P31/12\|A61K31/495\|C07D403/06\|C07D405/06	8
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00010927116B2	15/999701	20190010155	10927116	20180820	20190110	20210223	20190110	F. Hoffmann-La Roche	Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid	The present invention relates to a process for synthesizing a compound of formula (I),	C07D487/04	C07D487/04	1	C07D487/04	C07D487/04	1
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US20090099216A1	12/067781	20090099216		20060922	20090416		20090416	AstraZeneca	NOVEL ADENINE COMPOUND	A novel adenine compound represented by the formula (1):	C07D473/18	C07D473/18\|A61P11/02\|A61P31/20\|A61P29/00\|A61P43/00\|A61P31/18\|A61P27/02\|A61P37/08\|A61P31/14\|A61P17/00\|A61P37/02\|A61P31/12\|A61P11/06\|A61P35/00\|A61P31/04	15	A61K31/522	A61K31/522\|C07D473/18	2
968871	hepatitis C	C형간염	바이러스간염	B17.1\|B18.2	US	US20060258738A1	11/433378	20060258738		20060512	20061116		20061116	Icahn School of Medicine At Mount Sinai (Ismms, Mount Sinai School of Medicine of New York University)	Use of dronabinol for treatment of side effects of Hepatitis C therapy	The present invention provides methods for treating and preventing the gastrointestinal side effects associated with anti-HCV therapy comprising administering delta-9-tetrahydrocannabinol.	A61K38/21	A61K38/21\|A61K31/7056\|A61K31/353	3	A61K31/353	A61K31/353\|A61K38/21\|A61K31/7056	3
211726	Human immunodeficiency virus [HIV] disease	인체면역결핍바이러스병	인체면역결핍바이러스병	B20-B24	US	US20070202515A1	11/549019	20070202515		20061012	20070830		20070830	Pathologica	Promac signature application	The present invention is directed to ProMac signature genes and methods and kits for using the ProMac signature genes for diagnostic, prognostic, or monitoring ProMac associated diseases.	C12Q1/6883	C12Q1/6883\|C12Q2600/106\|B82Y30/00\|B82Y15/00\|C12Q2600/158\|C12Q2600/118	6	C12Q1/68	C12Q1/68\|C12M3/00	2
211725	Chronic viral hepatitis	만성 바이러스간염	바이러스간염	B18	US	US00006280728B1	09/245820		6280728	19990205		20010828	20010828	Mucos Pharma	Treatment of hepatitis C virus infection using a protease and a flavonoid	<p>The use of at least one hydrolytic enzyme and at least one flavonoid shows better activity than &agr;-interferon or ribavirin in the treatment of diseases caused by hepatitis C viruses.</p>	A61K38/4826	A61K38/4826\|A61K38/4873	2	A61K38/48	A61K38/48	1
211725	Chronic viral hepatitis	만성 바이러스간염	바이러스간염	B18	US	US00009611289B2	14/120366	20140371190	9611289	20140514	20141218	20170404	20141218	Intercept Pharmaceuticals	Farnesoid X receptor modulators	The present invention provides a compound of formula (I):	A61K31/575	A61K31/575\|A61P13/00\|A61P43/00\|A61P11/00\|C07J71/001\|C07J41/0061\|C07J31/006\|C07J9/005\|A61P1/00\|A61P1/16	10	A61K31/56	A61K31/56\|C07J9/00\|C07J41/00\|C07J71/00\|C07J31/00	5
211725	Chronic viral hepatitis	만성 바이러스간염	바이러스간염	B18	US	US20050042226A1	10/875528	20050042226		20040625	20050224		20050224	Trillium Therapeutics	Treatment of chronic human viral hepatitis	The use of Fgl2 inhibitors to treat and control the progression of human Hepatitis B virus-induced hepatitis is described. Inhibitors of Fgl2 include antibodies to Fgl2.	A01K67/0276	A01K67/0276\|A01K2267/0337\|C07K14/75\|A01K2227/105\|A61P31/20\|A01K2217/075\|C12N15/8509\|A61K2039/505\|C07K16/40	9	A61K39/42	A61K39/42\|C12Q1/68	2
211725	Chronic viral hepatitis	만성 바이러스간염	바이러스간염	B18	US	US20110124670A1	13/054011	20110124670		20090714	20110526		20110526	Novartis	Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis	The invention relates to the use of a pyrimidylaminobenzamides of formula I	A61K31/506	A61K31/506\|A61P43/00\|A61K31/4184\|A61P31/12\|A61K31/4178\|A61P11/00\|A61K31/41\|A61P1/16\|A61K45/06	9	A61K31/506	A61K31/506\|A61P11/00\|A61P1/16	3
211725	Chronic viral hepatitis	만성 바이러스간염	바이러스간염	B18	US	US20130267549A1	13/911127	20130267549		20130606	20131010		20131010	Novartis	Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis	The invention relates to the use of a pyrimidylaminobenzamides of formula I	A61K31/506	A61K31/506\|A61P1/16\|A61K45/06\|A61P43/00\|A61K31/4184\|A61P31/12\|A61K31/4178\|A61P11/00\|A61K31/41	9	A61K31/506	A61K31/506\|A61K31/41\|A61K45/06	3
968869	Chronic hepatitis B	만성 B형간염	바이러스간염	B18.0-1	US	US20220313690A1	17/627708	20220313690		20200717	20221006		20221006	Enyo Pharma	SYNERGISTIC EFFECT OF EYP001 AND IFN FOR THE TREATMENT OF HBV INFECTION	The present invention relates to a synergistic combination of EYP001 and interferon for the treatment of hepatitis B.	A61K31/496	A61K31/496\|A61K9/0019\|A61P31/20\|A61K47/60\|A61K38/212	5	A61K31/496	A61K31/496\|A61K38/21\|A61P31/20\|A61K47/60\|A61K9/00	5
941134	Tinea unguium	손발톱백선	진균증	B35.1	US	US00005744469B	08/756996		5744469	19961126		19980428	19980428	Eli Lilly and Company	Method for treating dermatitis	<p>The invention provides a method for treating fungal dermatitis comprising administering an effective amount of 2-Methyl-4-(4-methyl-1- piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine to a patient in need thereof.</p>	A61K31/551	A61K31/551	1	A61K31/55	A61K31/55\|A61K31/38	2
941075	Chronic viral hepatitis C	만성 C형간염	바이러스간염	B18.2	US	US00009315545B2	14/680562	20150284429	9315545	20150407	20151008	20160419	20151008	Jolla Pharma	Hepcidin mimetic peptides and uses thereof	Compounds and methods are described herein that can be used to treat subjects for conditions related to hepcidin activity, such as but not limited diseases of iron metabolism, beta thalassemia, hemochromatosis, iron-loading anemias, alcoholic liver disease, or chronic hepatitis C.	C07K7/06	C07K7/06\|A61P1/16\|A61P3/00\|A61P7/00\|A61P7/06\|C07K7/02\|A61K38/00	7	C07K7/06	C07K7/06\|C07K7/02	2
941075	Chronic viral hepatitis C	만성 C형간염	바이러스간염	B18.2	US	US20080207567A1	11/813252	20080207567		20060102	20080828		20080828	Brinkmann, Volker\|Feutren, Gilles	Treatment of Hcv Disorders	S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV).	A61K31/661	A61K31/661\|A61P31/14\|A61K31/381\|A61P31/12\|A61K31/137\|A61P31/00\|A61P1/16\|A61P43/00\|A61K31/397	9	A61K31/66	A61K31/66\|A61K31/38\|A61P31/00	3
941075	Chronic viral hepatitis C	만성 C형간염	바이러스간염	B18.2	US	US20140018289A1	14/007499	20140018289		20120329	20140116		20140116	Novartis	New treatments of Hepatitis C virus infection	The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection.	A61K38/12	A61K38/12\|A61P31/14\|A61K38/13\|A61P1/16\|A61K31/7056\|A61K45/06\|A61K31/395\|A61K38/212\|A61P43/00\|A61K38/21	10	A61K38/13	A61K38/13\|A61K45/06	2
941075	Chronic viral hepatitis C	만성 C형간염	바이러스간염	B18.2	US	US20150139950A1	14/540469	20150139950		20141113	20150521		20150521	Novartis	ALISPORIVIR TO TREAT HEPATITIS C VIRUS INFECTION	The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection.	A61K38/12	A61K38/12\|A61P31/14\|A61K38/13\|A61P1/16\|A61K31/7056\|A61K45/06\|A61K31/395\|A61K38/212\|A61P43/00\|A61K38/21	10	A61K38/12	A61K38/12\|A61K38/21\|A61K31/7056\|A61K45/06	4
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00005153318B	07/591916		5153318	19901002		19921006	19921006	Burroughs Wellcome	3'-Azido nucleoside compound	<p>The present invention relates to 3'-azido purine nucleosides and their use in medical therapy, particularly for the treatment of human immunodeficiency virus and hepatitis B virus infections, to methods for their preparation and to compositions containing them.</p>	C07H19/16	C07H19/16\|A61P31/12	2	C07H19/00	C07H19/00\|A61K31/7052\|A61K31/708\|C07H19/16\|A61P31/12\|A61K31/7042\|A61K31/7076\|A61K31/70	8
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00005196194B	06/679621		5196194	19841207		19930323	19930323	University of California	Vaccines containing Hepatitis B S-protein	<p>Recombinant full-length Hepatitis B surface antigen protein is disclosed. This protein is useful in vaccines for the prevention of Hepatitis B infection.</p>	C07K14/005	C07K14/005\|Y10S530/826\|Y10S530/806\|C12N2730/10122\|A61K39/00	5	C12N15/51	C12N15/51\|A61K39/00\|C07K14/02	3
968871	hepatitis C	C형간염	바이러스간염	B17.1\|B18.2	US	US00008030307B2	12/324048	20090180983	8030307	20081126	20090716	20111004	20090716	Enanta Pharmaceuticals	Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease	The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:	C07K5/0812	C07K5/0812\|C07K5/06165\|A61K38/00\|A61P31/12	4	A61K38/12	A61K38/12\|C07D225/04\|C07K5/12\|A61K31/407\|A61K38/21\|A61K31/517\|A61K31/7052\|A61P31/12\|A61K31/47	9
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00005872206B	08/319376		5872206	19941006		19990216	19990216	Massachusetts General Hospital (MGH, Mass General)	Compositions and methods for interfering wtih hepatitis B virus infection	<p>The invention provides for compositions and methods for interfering with Hepatitis B viral infection that are based on the interaction of Hepatitis B virus X protein with a novel proteasome subunit.</p>	C07K14/005	C07K14/005\|C12N9/48\|C12N2730/10122\|C07K2319/00\|A61K38/00	5	A61K38/00	A61K38/00\|C07K2/00\|C12N9/48\|C12P21/04\|C07K14/02	5
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00010745767B2	15/879921	20180195136	10745767	20180125	20180712	20200818	20180712	Cynosure\|Faxitron Bioptics\|Gen-Probe\|Hologic	Compositions and methods for detecting hepatitis B virus	Compositions, methods and kits for detecting viral nucleic acids. Targets that can be detected in accordance with the invention include HBV and/or HIV-1 and/or HCV nucleic acids. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers that facilitate detection of very low levels of HBV nucleic acids.	C12Q1/706	C12Q1/706\|C12Q1/703	2	C12Q1/68	C12Q1/68\|C12Q1/70	2
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00006583279B1	09/770532		6583279	20010126		20030624	20030624	Becton, Dickinson and Company (BD)	Sequences and methods for detection of hepatitis B virus	<p>Primers and probes derived from the HBV DNA polymerase gene which facilitate detection and/or quantification of all presently known genotypes of HBV. Disclosed sequences may be used in a variety of primer and probe constructs for detection of HBV nucleic acids.</p>	C12Q1/706	C12Q1/706	1	C07H21/00	C07H21/00\|C07H21/04\|G01N33/576\|C12Q1/68\|C12P19/34\|G01N33/566\|C12Q1/70\|C12N15/09\|G01N33/53	9
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00007589077B2	10/477763	20040242533	7589077	20020517	20041202	20090915	20041202	Rakesh Kumar	Antiviral nucleosides	Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus.	C07D239/54	C07D239/54\|C07H19/06\|C07H19/23\|A61P31/22\|A61P31/12\|C07D403/04\|C07D491/04	7	A61K31/7068	A61K31/7068\|C07H19/06\|C07H19/09\|C07H19/073\|A61K31/7072\|C07H19/067\|C07D403/04\|A61K31/553\|C07D239/54\|A61K31/554\|C07D498/18\|C07D491/04\|A61P31/12\|C07H19/23	14
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00007473680B2	11/183205	20060030521	7473680	20050715	20060209	20090106	20060209	Novo Nordisk	Remodeling and glycoconjugation of peptides	The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.	C07K1/1077	C07K1/1077\|A61K38/00\|C07K14/505\|C07K1/13\|C07K9/00\|C07K1/006	6	A61K38/00	A61K38/00\|A61K38/14\|C12P21/06\|A61K38/16\|C07K14/505\|C07K1/00\|C07K1/13\|C07K1/107\|C07K9/00	9
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00008227594B2	12/467939	20100130440	8227594	20090518	20100527	20120724	20100527	Rakesh Kumar	Antiviral nucleosides	Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus.	C07D239/54	C07D239/54\|C07H19/23\|A61P31/22\|A61P31/12\|C07H19/06\|C07D403/04\|C07D491/04	7	A61K31/7068	A61K31/7068\|A61K31/7072\|C07H19/23\|C07D498/18\|A61K31/554\|C07D239/54\|C07D403/04\|A61P31/12\|A61K31/553\|C07D491/04	10
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00008377994B2	12/299997	20090306224	8377994	20060510	20091210	20130219	20091210	Evonik Degussa	Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions	The use of Sch?lpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described.	A61K9/1611	A61K9/1611\|A61K9/1694	2	A61K47/00	A61K47/00\|A61K31/19\|A61K47/02\|A61K9/20	4
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00008865881B2	13/400945	20120232133	8865881	20120221	20120913	20141021	20120913	California Institute of Technology (CALTECH)	Delivery of proteins using adeno-associated virus (AAV) vectors	Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors.	C07K16/109	C07K16/109\|C12N2750/14143\|A61P31/20\|C07K16/1045\|A61P31/18\|C12N7/00\|C12N2750/14141\|A61P31/12\|A61P31/14	9	C07H21/04	C07H21/04\|C12N15/63\|C07K16/10\|A61K48/00\|A61P31/18\|A61K31/713\|C12N7/02\|A61P31/12\|C12N15/13\|C12N15/861\|A61P31/20	11
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00009205079B2	14/642393	20150174115	9205079	20150309	20150625	20151208	20150625	Novira Therapeutics	Hepatitis B antiviral agents	Provided herein are compounds useful for the treatment of HBV infection in man.	A61K31/454	A61K31/454\|A61K45/06\|A61K31/404\|C07D401/12\|A61P31/12	5	A61K31/404	A61K31/404\|A61K31/454\|A61K45/06\|C07D401/00\|C07D401/12	5
968870	hepatitis B	B형간염	바이러스간염	B16\|B18.0-1	US	US00009592282B2	12/374214	20100062028	9592282	20070716	20100311	20170314	20100311	GSK (GLaxoSmithKline) Biologicals	Vaccines for malaria	surface antigen S derived from Hepatitis B virus, or a fragment thereof.	A61K39/015	A61K39/015\|A61P1/16\|A61P31/00\|A61P33/06\|C07K14/445\|A61P33/02\|A61K2039/6075\|C07K2319/40\|Y02A50/30	9	A61K39/015	A61K39/015\|A61K39/00\|C12N7/00\|C07K14/445	4

상품 미리보기

연락처 및 데이터 관리

판매제공처 홈페이지	판매담당자	연락처	이메일
www.BLT.kr	특허법인BLT	02-514-0104	khpark@blt.kr

제약 및 취소환불 규정

제약 및 취소/환불 규정 안내
데이터 상품은 디지털화된 상품의 특성상 반품, 취소, 환불 되지 않으나 데이터의 심각한 오류, 상이한 데이터에 한하여 구매자가 요구하는 경우 환불을 진행할 수 있습니다.

상품 Q&A

※ 본인의 글만 수정이 가능하며, 타인의 글에 댓글을 남길 수 없습니다.
※ 댓글이 달린 글은 수정과 삭제가 불가능합니다.

등록된 글이 없습니다.

비밀글

등록하기 취소하기

데이터 상품 상세검색